The Consumer & Prescriber Grant Program (also going by other names, including Attorney General Prescriber Grant Program) was a grant program established with fines paid by Pfizer in the Franklin v. Parke-Davis trial for False Claims Act violations relating to off-label use of gabapentin.[1][2]
Grant recipients
There were 24 original grant recipients.
External links
- Official website archival copy from March 2011. The website existed from 2008-2011.
References
- Lainie Rutkow, Stephen Teret. The Potential for State Attorneys General to Promote the Public's Health: Theory, Evidence, and Practice Robert Wood Johnson Foundation Public Health Law Research Program, via FOLIO, October 2010^
- DW Price, MA Raebel, DA Conner, LA Wright. Prescribers' and Organizational Leaders' Preferences for Education about Heavily Marketed Drugs. The Permanente Journal, 2008^
- Attorney Generals' Prescriber and Consumer Education Grant College of Pharmacy, 4 October 2011^
- DW Price, MA Raebel, DA Conner, LA Wright. Prescribers' and Organizational Leaders' Preferences for Education about Heavily Marketed Drugs. The Permanente Journal, 2008^
- Carl Elliott. Pharmed Out: an Interview With Adriane Fugh-Berman The Chronicle of Higher Education Blogs: Brainstorm, 22 May 2012^
- Federation of State Medical Boards www.fsmb.org, retrieved 2017-06-21^
- University of Vermont. University Communications : University of Vermont www.uvm.edu, 14 April 2006^
- Jennifer Nachbur. Advancing Integrity in Medical Education www.pewtrusts.org, The Pew Charitable Trusts, May 21, 2013^
- Christian J. Krautkramer. Neurontin and off-label marketing AMA Journal of Ethics, June 2006^